YZFyzfpeptide.comTesamorelin2mgFor Research Use Only
1 / 1
Research product specification
TSM2
Tesamorelin
For Research Use Only. Not for human or veterinary use.
Tesamorelin is listed for legitimate laboratory and research procurement. This 99%+ research-use product is available in 4 listed specifications. Review product codes, storage guidance and COA status, then request a wholesale quotation. Published COA documentation is available for selected specifications.
Volume discounts are available for larger purchasing plans. Please contact us for a quotation.
Delivery includedUsually within 7 days after dispatch
Quality resolutionRefund or replacement when approved
24/7 contactWholesale assistance on WhatsApp
Product profile
About Tesamorelin
Tesamorelin is a synthetic 44‑amino acid polypeptide analogue of growth hormone‑releasing hormone (GHRH). It works by activating GHRH receptors in the pituitary gland to stimulate the synthesis and pulsatile release of endogenous growth hormone (GH), thereby elevating insulin‑like growth factor‑1 (IGF‑1) levels. Tesamorelin is the first and only FDA‑approved treatment indicated for the reduction of excess abdominal fat in HIV‑infected patients with lipodystrophy, receiving initial U.S. approval in 2010. Its N‑terminal modification improves stability and pharmacokinetics compared to native GHRH, enhancing its clinical utility.
Main functions
1.Significant Reduction in Visceral Adipose Tissue (VAT): In patients with HIV‑associated lipodystrophy, tesamorelin effectively reduces abdominal VAT. A meta‑analysis of five randomized controlled trials demonstrated mean reductions of 27.71 cm² in VAT area, 1.18 kg in trunk fat, and 1.61 cm in waist circumference compared to placebo.
2.Improves Hepatic Steatosis: Significantly reduces hepatic fat percentage (mean reduction of 4.28%), showing potential therapeutic value for metabolic dysfunction‑associated steatotic liver disease (MASLD). Ongoing research is exploring its role in non‑alcoholic fatty liver disease (NAFLD) and obesity.
3.Increases Lean Body Mass: Increases lean body mass by a mean of 1.42 kg without affecting overall BMI, contributing to improved body composition.
4.Elevates IGF‑1 Levels: Restores physiological pulsatile GH secretion, effectively raising IGF‑1 levels to mediate anabolic and lipolytic effects.
5.Metabolic Safety Profile: Meta‑analysis shows no significant adverse effects on glycemic or lipid parameters, without increasing the risk of glucose metabolism disorders. Current evidence does not link tesamorelin to clinically apparent acute liver injury.
6.Convenient Once‑Daily Dosing: Administered via subcutaneous injection once daily, requiring reconstitution with the provided diluent before use.
Recommended audience
HIV‑infected adults with lipodystrophy, particularly those with central abdominal fat accumulation.
HIV‑positive patients with visceral adiposity and associated metabolic complications.
Populations under investigation for NAFLD and obesity‑related metabolic disorders in clinical research settings.
Order formatOne box accepted
QuotationConfirmed on WhatsApp
DeliveryShipping and duties included
DocumentationPublished COA or available on request
Research product specification
Product information
Tesamorelin is listed for legitimate laboratory and research procurement. This 99%+ research-use product is available in 4 listed specifications. Review product codes, storage guidance and COA status, then request a wholesale quotation. Published COA documentation is available for selected specifications.
Handling information
Storage guidance
Keep unopened lyophilized products protected from light and moisture; store at 2-8°C short term or -20°C long term. After reconstitution, refrigerate according to product documentation and minimize freeze-thaw cycles.
Customer-first resolution
Report quality concerns within 14 days of delivery
Contact us with the order number, batch details and available photos. Opened products are accepted for review. When a quality claim is approved, you may choose a full refund or replacement shipment.
